Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 957-962

  Ding, Song ^a   Du, Yong ping ^a   Lin, Nan ^a   Su, Yuan yuan ^a   Yang, Fan ^a   Kong, Ling cong ^a   Ge, Heng ^a   Pu, Jun ^a   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cardiovascular risk; Glucagon like peptide 1; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ADULT; CARDIOVASCULAR DISEASE; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; REPRODUCIBILITY; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 84981314109     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.199     Document Type: Review

References (46)

1. [1] Narayan, K.M.V., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F., Lifetime risk for diabetes mellitus in the United States. JAMA 290 (2003), 1884–1890.
2. [2] Booth, G.L., Kapral, M.K., Fung, K., Tu, J.V., Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 29 (2006), 32–37.
3. [3] Haffner, S.J., Cassells, H., Hyperglycemia as a cardiovascular risk factor. Am. J. Med. 115:Suppl. 8A (2003), 6S–11S.
4. [4] Coutinho, M., Gerstein, H.C., Wang, Y., Yusuf, S., The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999), 233–240.
5. [5] Khaw, K.T., Wareham, N., Bingham, S., Luben, R., Welch, A., Day, N., Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141 (2004), 413–420.
6. [6] Laakso, M., Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48 (1999), 937–942.
7. [7] Laakso, M., Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus: the Finnish studies. Ann. Intern. Med. 124 (1996), 127–130.
8. [8] Einarson, T.R., Machado, M., Henk Hemels, M.E., Blood glucose and subsequent cardiovascular disease: update of a meta-analysis. Curr. Med. Res. Opin. 27 (2011), 2155–2163.
9. [9] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008), 2545–2559.
10. [10] Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360 (2009), 129–139.
11. [11] ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008), 2560–2572.
12. [12] Motta, A.J., Koska, J., Reaven, P., Migrino, R.Q., Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat. Cardiovasc. Drug Discov. 7 (2012), 2–9.
13. [13] Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 16 (2014), 38–47.
14. [14] Monami, M., Cremasco, F., Lamanna, C., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res., 2011, 2011, 215764.
15. [15] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 6, 2009, e1000097.
16. [16] Jadad, A.R., Moore, R.A., Carroll, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control. Clin. Trials 17 (1996), 1–12.
17. [17] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
18. [18] Ades, A.E., Lu, G., Higgins, J.P., The interpretation of random-effects metaanalysis in decision models. Med. Decis. Mak. 25 (2005), 646–654.
19. [19] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ, 327, 2003, 557.
20. [20] Deeks, J.J., Higgins, J., Altman, D.G., Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, 2008, 243–296.
21. [21] Tobias, A., Assessing the influence of a single study in meta-analysis. Stata Tech. Bull. 47 (1999), 15–17.
22. [22] Altman, D.G., Bland, J.M., Interaction revisited: the difference between two estimates. BMJ, 326, 2003, 219.
23. [23] Li, X.H., Yu, F.F., Zhou, Y.H., He, J., Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose–response meta-analysis. Am. J. Clin. Nutr. 103 (2016), 818–829.
24. [24] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
25. [25] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
26. [26] Blonde, L., Jendle, J., Gross, J., et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385 (2015), 2057–2066.
27. [27] Lind, M., Hirsch, I.B., Tuomilehto, J., et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, 351, 2015, h5364.
28. [28] Home, P.D., Shamanna, P., Stewart, M., et al. Efficacy and tolerability of albiglutide versus placebo orpioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes. Metab. 17 (2015), 179–187.
29. [29] Pfeffer, M.A., Claggett, B., Diaz, R., ELIXA Investigators, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257.
30. [30] Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen-Bartmer, I., Guo, H., Aronson, R., Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes. Metab. 15 (2013), 1000–1007.
31. [31] Raz, I., Fonseca, V., Kipnes, M., et al. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment. Diabetes Care 35 (2012), 485–487.
32. [32] Pratley, R., Nauck, M., Bailey, T., 1860-LIRA-DPP-4 Study Group, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int. J. Clin. Pract. 65 (2011), 397–407.
33. [33] Bergenstal, R.M., Wysham, C., Macconell, L., DURATION-2 Study Group, et al. Efficacy and safety of exenatide once weekly versus sitagliptinor pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439.
34. [34] Buse, J.B., Bergenstal, R.M., Glass, L.C., et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154 (2011), 103–112.
35. [35] Davies, M.J., Donnelly, R., Barnett, A.H., Jones, S., Nicolay, C., Kilcoyne, A., HEELA Study Group, Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes. Metab. 11 (2009), 1153–1162.
36. [36] Diamant, M., Van Gaal, L., Stranks, S., et al. Once weekly exenatide compared with insulin glarginetitrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (2010), 2234–2243.
37. [37] Nauck, M.A., Duran, S., Kim, D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 (2007), 259–267.
38. [38] Garber, A., Henry, R., Ratner, R., LEAD-3 (Mono) Study Group, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
39. [39] Ahrén, B., Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabete Metab., 41, 2015 (6S3-6S8).
40. [40] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
41. [41] Bose, A.K., Mocanu, M.M., Carr, R.D., Brand, C.L., Yellon, D.M., Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005), 146–151.
42. [42] Zhao, T., Parikh, P., Bhashyam, S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317 (2006), 1106–1113.
43. [43] Ratner, R., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B.J., Shen, L., Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc. Diabetol., 10, 2011, 22.
44. [44] Marso, S.P., Lindsey, J.B., Stolker, J.M., et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies. Diab. Vasc. Dis. Res. 8 (2011), 237–240.
45. [45] Sun, F., Yu, K., Wu, S., et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res. Clin. Pract. 98 (2012), 386–395.
46. [46] Inzucchi, S.E., McGuire, D.K., New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117 (2008), 574–584.